The Fast-Changing GLP-1 Landscape and Employee Coverage
GLP-1 drugs are reshaping diabetes and weight-loss care. Here’s how new treatments, pricing shifts, and coverage decisions impact employer health plans.
GLP-1 Drugs and Youth: Why More Research Is Needed Before Expanding Use
When it comes to kids and GLP-1s, careful consideration is just as vital as clinical innovation.
Childhood Obesity in Europe: Could GLP-1 Drugs Play a Role?
Childhood obesity in Europe is rising. Experts debate GLP-1 drugs for kids: balancing safety, access, and prevention in tackling this epidemic.
In the Age of GLP-1 Weight-Loss Medications, Lifestyle Changes Still Matter
Doctors emphasize lifestyle changes first in obesity care, even with GLP-1 drugs. Learn why combining medication with therapy drives lasting results.
U.S. Young Adults Are Eligible for GLP-1RAs, But Few Receive Them
New research reveals that approximately 17 million adolescents and young adults in the U.S. meet the criteria for GLP-1RA therapy, but it’s complicated.
The Psychological and Social Complexities of GLP-1 Drugs
Exploring the psychological and social impacts of using GLP-1 drugs for weight loss.
GLP-1 and Akkermansia, the Rest of the Story
It is possible to encourage one’s personal stock of the helpful bacterium by eating its favorite foods, like high-fiber vegetation and nondigestible carbs.
GLP-1 and Akkermansia, a Glowing Prospect
The mucus-loving bacterium Akkermansia muciniphila offers a glimpse of an exciting future of drug-free therapy that achieves sustainable weight loss.
GLP-1 and Akkermansia
One of the interesting challenges taken up by scientists in the past few years has been how to convince a body to make more GLP-1 on its own.
Maximizing GLP-1 Treatment Success
A new joint advisory from four major clinical organizations provides a much-needed roadmap to help patients get the most out of GLP-1 medications for obesity.